top of page
Picture1.png
193785529_m_normal_none.png

A New Paradigm in Oncology and Hereditary Disease Therapeutics

The First A.I. Designed Mini-CARTM Therapeutics Targeting

Solid Tumors and Hereditary Disease

Solid Tumor Cancers

Hereditary Disease

CAR-Directed BioSpheres (Mini-CARTM) are innovative therapeutic agents that emulate the functions of T cells, Natural Killer cells, or macrophages. These miniaturized biospheres, derived from an allogeneic parent cell, house chimeric antigen receptors (CARs) and optional checkpoint inhibition tags. This unique design enables highly targeted and safe release of apoptotic proteins to diseased cells, offering a promising solution to the limitations of conventional CAR whole cell therapies in treating a variety of diseases, including solid tumor cancers and hereditary disease.

CAR T-cell Attacking Cancer Tumor
Picture1.png
Caravan Management Team

Board of Directors

Caravan Board of Directors

Leadership

Caravan Science and Business Advisory Board

Science & Business Advisory Board

Advancing Precision Medicine to New Levels

Boundless Platform Applications Across Multiple Diseases and Diagnostics

CAR-Mediated BioSphere Therapeutic
Mini-CAR
TM 

Introducing the mini-CAR Therapeutic: Advancing Precision Medicine

​

At Caravan Biologix, our focus is on leveraging the Mini-CAR technology to address critical human diseases. Our therapeutic platform provides a versatile foundation for developing nearly unlimited differentials of Mini-CAR that can be tailored to treat different human diseases, demonstrating our dedication to advancing healthcare on multiple fronts.

​

In addition to developing our own pipeline of Mini-CAR drugs, a key aspect of our strategy involves collaborating with other biotech companies, offering our platform for the development of their own Mini-CAR driven pipelines. The out licensing of our platform technology can result in the production of standalone therapies or co-therapeutics alongside their existing medicines, showcasing our commitment to advancing healthcare through strategic partnerships and collaborations.

​

In addition to licensing, we are actively utilizing the Mini-CAR platform to develop our own therapeutic pipeline, meticulously designed to enhance human health and showcase the platform's full range of druggable properties. This strategic approach ensures that our research not only benefits our own pipeline but also contributes to the broader understanding and utilization of the Mini-CARTM technology in the medical field.

​

Mini-CARs are innovative drug candidates designed to emulate the functions of immune cells. Our Mini-CAR pipeline is focused on precision targeting of specific diseases, with a particular emphasis on cancer therapy. We are exploring the potential of releasing perforins, granzymes, and p53 to solid tumor cancers, offering a more effective alternative to whole-cell-based treatments. Additionally, our approach involves restoring the immunomodulatory function of Natural Killer cells by targeting and releasing wild type granules, thereby preventing certain types of Hemophagocytic Lymphohistiocytosis (HLH). Furthermore, we are leveraging this technology to expanded clonal B-cell populations in systemic lupus erythematosus (SLE), addressing the underlying causes of this disease and aiming to improve patient outcomes.

Properties Beyond Whole Cell CAR Based Therapeutic Technologies

Allogenic

Multi-dosing Properties

Tumor-Honing

Migratory Tuning Capabilities

Ultra Low Cytotoxicity

Elimination of CRS

Superior Barrier Crossing

Organ Directed Treatment

Homogeneous and Low-Cost Manufacturing

Competitive Reproducibility

Mini-CAR
Enhanced Precision Immuno Therapy

Picture3.png

Allogenic

Our Mini-CARs are derived

from allogenic and differentiated iPSCs

Biomarker

Targeting

We use advanced AI programming to select the best CARs based on Immunological Synapse quality 

Tumor

Accessibility

The Mini-CAR is the optimal size to deeply penetrate solid tumors for maximum killing power

CRS

Prevention

With no genetic baggage or cytotoxic proteins, our Mini-CARs vastly reduce the occurrence of cytokine storm 

Cytokine

Control

Our proprietary upstream cellular activation process allows for the expression of any desired therapeutic peptide or nucleic acid  

Barrier

Crossing

Our Mini-CARs contain multiple properties that allow them to cross tissue barriers with unprecedented efficiency

193785529_m_normal_none.png

Our Research Partners

Bruker Inc.
Reprocell Inc.
TD2 Inc.
MDimune Inc. and BioDrone Inc.
Colorado Health & Tech Center
Picture1.png

Partnering

Contact Caravan Biologix to Build Your Mini-CAR Therapeutic Pipeline

Our robust partnering program can take your current therapeutic approach to new highly efficacious levels safer than other technologies.

​

Caravan Biologix Inc.
Caravan News Releases

Caravan Biologix in the News

BUSINESS WIRE - Caravan Biologix, Inc. Enhances its Scientific and Business Advisory Board with New Experts
December 2, 2023

BUSINESS WIRE - Caravan Biologix, Inc. is Awarded Two Issued Patents in Australia, and Japan
 
July 10, 2024

BUSINESS WIRE - Caravan Biologix, Inc. Adds New Members to its Board of Directors
 
September 15, 2024

bottom of page